Participants were randomly allocated ( 4:4:5 ratio ) to receive PCV10 in addition to routine immunisations either as a two-dose prime and boost ( 2 +1 ) , three-dose prime ( 3 +0 ) , or two doses after completion of the initial study phase ( 0 +2 ) .